Public procurement in Catalonia has to overcome various challenges, such as the end goal for medicines, technology and, in general, new healthcare solutions in hospitals. The CataloniaBio & HealthTech Innovation Workgroup brought together six experts from companies, hospitals and legal services for the Hospital Connection event And how do you buy? on 22 February in Barcelona to debate the current framework and how it is expected to change.

New models for the relationship between businesses (supplier) and hospitals (purchaser) must be developed and the imbalance between large corporations and hospitals is a barrier to negotiations, agreed Ferran Rodríguez, head ...

Interview to Jaume Amat, president of CataloniaBio & HealthTech since 2018 and CEO of Specipig:

It has been one year since the merger of CataloniaBio and the HealthTech Cluster. How would the board take stock of the past year?

When we started this new era, we believed that the merger addressed a trend and a real need in the sector resulting from the transversal nature of new healthcare solutions. One year later, we’re more sure of this than ever. As an association, we are much more diverse and, therefore, much richer and with more complimentary assets. We can be proud ...

Montserrat Vendrell has been named the new president of the Pompeu Fabra University Board of Trustees (UPF), taking over from Núria Basi, who had held the position since 2008. The board is the body through which society participates in the UPF.

Vendrell is a partner in the venture capital fund Alta Life Sciences, member of the CataloniaBio & HealthTech board of directors and president of the executive committee at the Pasqual Maragall Foundation.

She is the third woman in a row to hold the position of president of the UPF Board of Trustees.

Enantia, CataloniaBio & HealthTech member, has again succeeded in applying cocrystallisation technology to a new family of compounds, the cannabinoids.

Cannabinoids, especially cannabidiol (CBD) and tetrahydrocannabinol (THC), plays an important role in a number of biochemical pathways. Besides Sativex® and Epidiolex®, the only two approved drugs containing CBD, the potential of cannabinoids to be used to treat a large number of medical conditions is very high as is shown by the number of ongoing clinical trials.

Enantia has developed new cannabinoid cocrystals to allow their purification from complex mixtures (natural and synthetic) and to obtain improved active pharmaceutical ingredients and ...

FreeOx Biotech has taken on AEC Partners as a strategic partner in the company to accelerate development and marketing of its drug to treat brain ischemia. Both companies are members of CataloniaBio & HealthTech.

The priority drug is Ox-01, which is about to begin phase-III clinical trials. AEC Partners analysed the brand positioning, financial needs and expected return. At the same time, negotiations are already under way with potential licensees in various world markets.

Jordi Esclusa, managing partner at AEC Partners, and Nerea Alonso, partner in the Barcelona offices of AEC Partners, explain that “It is highly satisfying to lead ...